Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Daily News

先前的动脉粥样硬化会升高急性心肌梗死后的死亡风险

Michael O'Riordan

December 09, 2016

News Daily News

Prior Atherosclerosis Ups the Risk of Dying After Acute MI

Michael O'Riordan

December 09, 2016

News Daily News

Los Antecedentes de Aterosclerosis Aumentan el Riesgo de Morir Post-IAM

Michael O'Riordan

December 09, 2016

News Daily News

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Michael O'Riordan

December 01, 2016

News Daily News

Evolocumab Modifies IVUS-Detected Coronary Atherosclerosis: Topline Results From GLAGOV

Michael O'Riordan

September 20, 2016

News Industry News

Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled

November 23, 2015

News Industry News

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

September 28, 2015

News Industry News

A Competitive Analysis of the Global Acute Coronary Syndrome (ACS) Therapeutics Market

May 28, 2015

News Industry News

Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia

July 30, 2014

News Daily News

IVUS Guidance Reduces Stent Thrombosis, MACE Compared to Angiography

December 08, 2013

News Daily News

El Guiado mediante IVUS Reduce la Trombosis del STENT y los MACE comparado con la Angiografía

December 08, 2013

Advertisement

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

先前的动脉粥样硬化会升高急性心肌梗死后的死亡风险

Prior Atherosclerosis Ups the Risk of Dying After Acute MI

Los Antecedentes de Aterosclerosis Aumentan el Riesgo de Morir Post-IAM

PCSK9 Variants Linked With Lower LDL Cholesterol, Increased Diabetes Risk

Evolocumab Modifies IVUS-Detected Coronary Atherosclerosis: Topline Results From GLAGOV

Regeneron and Sanofi Announce 18,000-Patient ODYSSEY OUTCOMES Trial of Praluent® Injection Fully Enrolled

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

A Competitive Analysis of the Global Acute Coronary Syndrome (ACS) Therapeutics Market

Sanofi and Regeneron Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia

IVUS Guidance Reduces Stent Thrombosis, MACE Compared to Angiography

El Guiado mediante IVUS Reduce la Trombosis del STENT y los MACE comparado con la Angiografía

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content